Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01955499
Title Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

mantle cell lymphoma

lymphoplasmacytic lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

marginal zone B-cell lymphoma

Therapies

Ibrutinib + Lenalidomide

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.